- Market Capitalization, $K 117,170,240
- Shares Outstanding, K 2,529,582
- Annual Sales, $ 47,822 M
- Annual Income, $ 8,820 M
- 60-Month Beta 0.59
- Price/Sales 2.57
- Price/Cash Flow 8.00
- Price/Book 1.46
|Period||Period Low||Period High||Performance|
| || |
+0.54 (+1.18%)since 11/08/23
| || |
-7.27 (-13.57%)since 09/08/23
| || |
-0.60 (-1.28%)since 12/08/22
These stocks aren't popular on the market right now, but investors shouldn't let that scare them off.
Enterprise cloud data management software provider Informatica Co. (NASDAQ: INFA) saw its shares surge 23% on its impressive Q3 2023 earnings report. The compa
Stocks closed the week with a strong rally, but the rally may reverse when investors get the latest information about inflation and retail stocks next week
There are very good reasons that stocks generally gain in value after a company receives %OrphanDrug designation (ODD). A study published in Orphanet Journal of Rare Diseases showed that the average stock...
Pharmaceutical stocks aren't having a banner year; notably, two large pharmaceutical companies recently plunged to 52-week lows
Now could be a great opportunity to buy low.
NetworkNewsWire Editorial Coverage : GLP-1 agonists have become incredibly popular obesity drugs, reshaping the standard of care as people increasingly turn to the new class of drugs in lieu of conventional...
EQNX::TICKER_START (NASDAQ:LEXX),(NYSE:JNJ),(NYSE:SNY),(NASDAQ:AMGN),(NYSE:NVS) EQNX::TICKER_END
The healthcare sector faces a selloff as pharmaceutical giants report lackluster earnings; even Amgen's strong results failed to prevent selling in the sector
If you’re looking for a top exchange-traded fund (ETF) to hold in your portfolio and which can ...
|3rd Resistance Point||46.85|
|2nd Resistance Point||46.67|
|1st Resistance Point||46.49|
|1st Support Level||46.13|
|2nd Support Level||45.95|
|3rd Support Level||45.77|